A COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN PORTUGAL

被引：0
|
作者：
Pinheiro, B. [1 ]
Cardoso, M. [1 ]
Borges, M. [2 ]
Launonen, A. [3 ]
Ho, R. [3 ]
Miguel, Silva L. [1 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, P-11 Lisbon, Portugal
[2] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA56
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [21] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Vacirca, Jeffrey
    Tabbara, Imad
    Acs, Peter
    Shumaker, Grace
    BLOOD, 2010, 116 (21) : 1157 - 1157
  • [22] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
    Arcari, Annalisa
    Chiappella, Annalisa
    Valenti, Vanessa
    Zanlari, Luca
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Spina, Michele
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Della Seta, Roberta
    Vallisa, Daniele
    BLOOD, 2014, 124 (21)
  • [23] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Jeffrey L. Vacirca
    Peter. I. Acs
    Imad A. Tabbara
    Peter. J. Rosen
    Peter Lee
    Eric Lynam
    Annals of Hematology, 2014, 93 : 403 - 409
  • [24] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Vacirca, Jeffrey L.
    Acs, Peter I.
    Tabbara, Imad A.
    Rosen, Peter J.
    Lee, Peter
    Lynam, Eric
    ANNALS OF HEMATOLOGY, 2014, 93 (03) : 403 - 409
  • [25] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [26] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [27] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [28] COST-EFFECTIVENESS ANALYSIS OF TAFASITAMAB IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GREECE
    Karaiskou, M.
    Avgitidou, A.
    Vostitsanou, Z.
    Batsi, M.
    Bungey, G.
    Prawitz, T.
    Peter, B.
    Stafylas, P.
    VALUE IN HEALTH, 2023, 26 (12) : S151 - S151
  • [29] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) : 201 - 204
  • [30] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
12345